Diabetes: Once weekly insulin could be as effective as daily injections, studies indicate

The effectiveness of a new class of once weekly basal insulin, called efsitora alfa, has been tested in two separate phase 3 trials: one in patients with type 1 diabetes and one in those with type 2. The results, presented at the European Association for the Study of Diabetes in Madrid on 10 September and simultaneously published in the New England Journal of Medicine and the Lancet, show that the weekly injection is as effective as a daily injection of a long acting basal insulin, although with type 1 diabetes there was a higher incidence of hypoglycaemia, including severe hypoglycaemia.